<DOC>
	<DOCNO>NCT02133378</DOCNO>
	<brief_summary>A new topical hemostatic agent compose specifically-formulated porous collagen matrix , coat one side thin protein bond layer ( know NHS-PEG ) report extremely effective , addition traditional mean , terminate bleeding cardiac operation control rate high 97,5 % . The investigator compare hemostatic agent ( Hemopatch ; Baxter Inc , Deerfield , IL ) traditional optimized hemostasis routine . Following sample size calculation , prospective randomize study design , 100 patient treat Hemopatch 100 patient receive traditional optimize hemostasis routine ( comparison group ) . To make two cohort comparable possible enrollment restrict moderately bleed vascular anastomosis Dacron graft ascend aorta moderately bleed transversal aortotomy . Study endpoints follow : rate successful intraoperative hemostasis ( identify cessation bleed less 3 minute application ) time require hemostasis ; overall postoperative bleeding ; rate transfusion blood product ; rate surgical revision bleeding ; postoperative morbidity ; intensive care unit stay .</brief_summary>
	<brief_title>Prospective Clinical Trial Hemopatch Topic Hemostatic Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Surgery Ascending Aorta Dacron Graft transverse Aortotomy Moderate bleeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bleeding</keyword>
	<keyword>Hemostatic</keyword>
</DOC>